NCT03043664View on ClinicalTrials.gov

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

May 3, 2021

Study Completion Date

June 7, 2022

Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
DRUG

Lanreotide

Somatuline depot (lanreotide) 90 mg SQ every 3 weeks

DRUG

Pembrolizumab

Keytruda (pembrolizumab) 200 mg IV every 3 weeks

Trial Locations (2)

27710

Duke University Medical Center, Durham

29169

Lexington Medical Center, Columbia

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Ipsen

INDUSTRY

lead

Duke University

OTHER